Sanofi (SNY) has become the market authorization holder in Canada for Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine. Nuvaxovid represents another step in Sanofi’s commitment to building a diverse portfolio of best-in-class vaccines and addressing respiratory diseases for Canadians across their lifespan. Sanofi will make Nuvaxovid available in Canada for the fall 2026-2027 season.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Dianthus initiated with an Outperform at Wolfe Research
- Balanced Risk-Reward Amid Promising Lunsekimig Data and Valuation Uncertainty Supports Hold Rating
- Trump Trade: U.S. strengthens tariffs on steel, aluminum, copper imports
- Anthropic Finalizes $400 Million Takeover of AI Startup Coefficient Bio
- White House says imposing tariffs on patented pharmaceutical products